APA (7th ed.) Citation

KS, D., P, K., RV, L., A, W., MC, T., JP, C., . . . JJ, R. (2026). A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination. Journal of neuro-oncology, 176(3), 185. https://doi.org/10.1007/s11060-026-05446-1

Chicago Style (17th ed.) Citation

KS, Dixit, et al. "A Phase 2, Open Label, Clinical Trial of Pre-surgical and Adjuvant Treatment of Recurrent Glioblastoma with Tremelimumab and Durvalumab Alone and in Combination." Journal of Neuro-oncology 176, no. 3 (2026): 185. https://doi.org/10.1007/s11060-026-05446-1.

MLA (9th ed.) Citation

KS, Dixit, et al. "A Phase 2, Open Label, Clinical Trial of Pre-surgical and Adjuvant Treatment of Recurrent Glioblastoma with Tremelimumab and Durvalumab Alone and in Combination." Journal of Neuro-oncology, vol. 176, no. 3, 2026, p. 185, https://doi.org/10.1007/s11060-026-05446-1.